SPRY

ARS Pharma is a one-product story built entirely on neffy, the first FDA-approved needle-free intranasal epinephrine. The MD&A frames a $3.5B+ U.S. addressable market off 6.5M autoinjector patients, and management is doubling down — expanding the internal sales force from ~106 to ~150 in Q2 2026, layering on ~70 ALK co-promote reps (live since June 2025), DTC linear TV from June 2025, and the 'Get neffy on Us' initiative launched November 2025. The problem is that the numbers do not match the narrative. FY2025 revenue was $84.3M, down 5.5% YoY from FY2024's $89.1M — the first full year of a major commercial launch should be ramping, not contracting. With shares trading at $7.61 (market cap $756M) on a 9.0x P/S of shrinking revenue, today's -27.8% gap almost certainly reflects a new datapoint (likely Q1'26 10-Q disappointment) that confirms the launch is stalling.

The income statement is alarming. Operating income swung to -$179M (margin -212.9%), net loss -$171M, and FY2024's $8M profit is revealed in hindsight as a one-time accounting quirk rather than a sustainable inflection. Cash burn matches: operating cash flow of -$171M against just $41.3M of cash on hand. Liabilities more than doubled YoY (+126.2%) to $213M, long-term debt sits at $96.4M, equity collapsed -55.5% to $114M, and the accumulated deficit deepened to -$295M. R&D was cut 33% — consistent with an 'all-in on commercialization' posture, but it also means there is no pipeline cushion if neffy underperforms. At current burn, ARS has roughly three months of cash on the balance sheet, meaning a dilutive raise or expensive debt is near-certain.